pricing process for Medigen vaccines 結果共1筆

Premier Chen Chien-jen discusses the pricing process and confidentiality agreements surrounding Medigen vaccines, stating that negotiations with the Centers for Disease Control (CDC) are ongoing. As a publicly listed company, any decisions about publicizing the government contract require shareholders’ approval. Chen emphasizes the government’s belief in vaccination as the best measure against the pandemic. Medigen had positive results from phase one trials and clinical experiments, leading to phase two development. The World Health Organization (WHO) conducted unity trials with four other countries after being unable to proceed with phase three trials due to Taiwan’s low COVID-19 case statistics. Chen disputes rumors about a 30-year embargo on clinical results, calling it fake news and clarifying that all official documents have a preservation period. He also refutes accusations that over a thousand Medigen shareholders are members of the Democratic Progressive Party (DPP), calling them ＂imaginary numerical figures.＂ Chen hopes to disclose the information as soon as possible to maintain public trust, but it can only happen after negotiations and respecting existing confidentiality agreements.